![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 43, 39968-39973, October 26, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Bacteriology, University of Wisconsin, Madison, Wisconsin 53706
Received for publication, June 21, 2001, and in revised form, August 23, 2001
| |
ABSTRACT |
|---|
|
|
|---|
CooA is a CO-sensing protein that activates the
transcription of genes encoding the CO-oxidation (coo)
regulon, whose polypeptide products are required for utilizing CO as an
energy source in Rhodospirillum rubrum. CooA binds to a
position overlapping the Rhodospirillum rubrum is a photosynthetic bacterium
capable of oxidizing carbon monoxide (CO) to CO2 with
concomitant evolution of H2, which is coupled to energy
generation (1). The components of the CO-oxidizing (coo)
regulon, which are produced only in the presence of exogenous CO, are
encoded by two operons, and their expression is controlled by CooA, a
transcriptional activator that binds CO under reducing conditions and
is itself expressed constitutively from an adjacent operon (2). The
structural components of the CO-oxidizing system include CooS (CO
dehydrogenase), which oxidizes CO to CO2, CooF, a
CooS-associated iron-sulfur protein that donates reducing equivalents
to CooH, a CO-tolerant hydrogenase (3-5).
CooA is a heme-containing protein that belongs to the cAMP receptor
protein (CRP1 (6)) and the
fumarate and nitrate reductase activator protein (FNR (7)) superfamily
of transcriptional activator proteins. All three proteins are
homodimers when competent to bind DNA, and the structures of CooA and
CRP reveal effector-binding and DNA-binding domains in each monomer.
The structure of CooA in the reduced (FeII) form has been
solved recently (8) and revealed that the general folding topology of
CO-free CooA and cAMP-bound CRP (9) were similar (see Fig. 1 below). In
the case of CRP, only the effector (cAMP)-bound structure has been
solved (9), and for CooA, only the effector (CO)-free structure is
known (8). Significant differences were observed in the positions of
the DNA-binding domains of the two proteins. However, because both
proteins bind to similar DNA sequences (2), it is assumed that the
DNA-binding regions of the effector (CO)-bound form of CooA should
adopt a roughly similar orientation compared with that of effector
(cAMP)-bound CRP (8). This suggests that a rotation of ~180° of the
recognition helices occurs in CooA upon effector binding (see Fig. 1).
In CooA, CO binds to the heme in the effector-binding domain and causes
a conformational change that subsequently positions the DNA-binding
domain to interact effectively with target DNA. Some CooA variants have
been described with varying levels of effector-independent activity
(10). These have been referred to as "CooA*" by analogy to the
variants of CRP (denoted CRP* (11)) with cAMP-independent activity. In
CooA, some of the substitutions with this phenotype affect the heme
region directly (10), whereas others affect residues in and around the
long "C helices" (Fig. 1) that form the dimer interface.2
35 element of the PcooF promoter,
similar to the arrangement of class II CRP (cAMP receptor protein)- and
FNR (fumarate and nitrate reductase activator
protein)-dependent promoters when expressed in
Escherichia coli. Gain-of-function CooA variants were
isolated in E. coli following mutagenesis of the portion of
cooA encoding the effector-binding domain. Some of the
mutations affect regions of CooA that are homologous to the activating
regions (AR2 and AR3) previously identified in CRP and FNR, whereas
others affect residues that lie in a region of CooA between AR2 and
AR3. These CooA variants are comparable to wild-type (WT) CooA in DNA binding affinity in response to CO but differ in transcription activation, presumably because of altered interactions with E. coli RNA polymerase. Based on predictions of similarity to CRP and FNR, loss-of-function CooA variants were obtained in the AR2 and
AR3 regions that have minimal transcriptional activity, yet have
WT-like DNA binding affinities in response to CO. This study demonstrates that WT CooA contains AR2- and AR3-like surfaces that are
required for optimal transcription activation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (44K):
[in a new window]
Fig. 1.
CooA and CRP monomers showing residues
relevant to the current study in space-filled display; the significant
reorientation of the DNA-binding domain in effector-bound CRP compared
with effector-free CooA is apparent. The approximate location of
the proposed activating regions are circled, and the C
helices that form the dimerization interface in each protein is noted.
The
sheets that join at the AR3 are termed the 4/5 loop. Left
panel, a similar display of effector (cAMP)-bound CRP (Protin Data
Bank no. 1g6n). Right panel, the "B" monomer of effector
(CO)-free CooA in the FeII state (PDB no. 1ft9). The exact
locations of activating regions (AR) will certainly be
altered upon CO binding. The CRP residue Glu96, referred to
in the text, lies immediately in front of His21 in this
view but is not shown for reasons of clarity.
Members of the CRP/FNR/CooA family respond to specific intracellular
signals, bind specifically to one or more promoter regions, and
activate transcription through contacts with RNA polymerase (RNAP
(11-13)). RNAP (Fig. 2) consists of two
molecules of the
subunit, one molecule each of the
and
'
subunits, and one of several
subunits. The
subunit can be
further divided into an N-terminal domain (
-NTD) and a C-terminal
domain (
-CTD), which are joined by a flexible linker. These domains,
along with the
subunit, have distinct functions in transcription
activation through specific interactions with activator proteins. CRP
is known to activate transcription in distinct ways at three different classes of promoters (classes I, II, and III (14)).
|
At class II CRP-dependent promoters, CRP binds to a site
centered around
41.5 in which the CRP-binding site overlaps the
35
promoter element. At these promoters (Fig. 2), the "upstream" subunit of CRP contacts the RNAP
-CTD through activating region 1 (AR1), whereas the "downstream" subunit of CRP contacts RNAP
-NTD through a second surface termed AR2 (Figs. 1 and 2). The AR2 of
CRP is comprised of a surface patch of negatively charged amino acid
residues in the effector-binding domain that interacts with a
positively charged patch of amino acids on the
-NTD of RNAP (15).
AR2 primarily affects the rate of isomerization from a "closed" to
an "open" promoter complex (15). AR3 is known to be important for
FNR function at class II promoters (18), but it apparently exists in a
non-functional "cryptic" form in CRP (16). A functional AR3 can be
created in CRP by point mutations that change Lys52 to a
neutral or negatively charged residue (19, 20). AR3 of CRP is a
surface-exposed
-turn region (named the "4/5 loop"; Fig. 1) in
the effector-binding domain comprised of predominantly negatively
charged residues (16), which interacts with a positively charged
surface patch on the
subunit (17).
Previous studies have shown that CooA activates transcription at
PcooF when expressed heterologously in vivo in
Escherichia coli (21) and that CooA can interact with
E. coli RNA polymerase at PcooF in vitro,
dependent on CO and the
-CTD of RNAP (13). Furthermore, studies
using RNAP variants with single substitutions in the
-CTD revealed
that the contacts between CooA and the E. coli
-CTD are
similar but not identical to those between CRP and
-CTD at class II
promoters (13). Because the CooA target sites, PcooF (13) and
PcooM (22), are typical of class II-dependent
promoters, comparison of potential CooA·RNAP interaction sites
with those that are known for CRP and FNR will suggest general
properties of the CRP/FNR/CooA family in terms of RNAP interactions.
This work characterizes the AR2 and AR3 regions of CooA, with
implications for the properties of the CRP/FNR superfamily of activator proteins.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Strains and Plasmids--
The construction of E. coli
strains expressing WT CooA and CooA variants and strains containing a
chromosomal
-galactosidase reporter system was described previously
(21). Site-directed variants were constructed in a pKK223-3-based
plasmid expression system as described previously (21).
Random Mutagenesis and Screen for Suppressors--
Random
mutations affecting the effector-binding domain (residues 1-131) of
CooA variants H77E and H77K were created using error-prone polymerase
chain reaction in two separate mutagenesis reactions that were adapted
from Vogel and Das (23) and from Fromant et al. (24). The
mutagenized segments were then cut with EcoRI and
ClaI (Promega) and gel-purified. The resulting mutagenized
fragment was ligated into a digested pKK223-3 vector encoding the
wild-type (WT) C terminus of CooA (residues 132-222). The resulting
pool of plasmids, encoding a randomly mutagenized CooA effector-binding
domain fused to a WT CooA DNA-binding domain, was transformed into the
E. coli strain in which
-galactosidase is expressed from
PcooF, a CooA-dependent promoter. Clones were
screened for significant activity in the presence of CO, using
MOPS-buffered agar plates (10) containing 40 µg/ml
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-gal)
and 450 µg/ml ampicillin. Plates were incubated anaerobically in the
presence of CO for 2 days at 30 °C. After storing the plates aerobically at 4 °C to allow color development, blue colonies were
isolated and corresponding plasmids containing cooA were sequenced to determine the mutations that were responsible for the
gain-of-function phenotype.
Because of the mutagenesis method, most sequenced mutants contained several mutations. These were then individually recreated by site-directed mutagenesis in a WT cooA background (i.e. encoding the normal His at position 77), and all further analyses were carried out with those strains. Putative loss-of-function variants were similarly created by site-directed mutagenesis in a WT cooA background and verified by sequencing.
Quantitative in Vivo
-Galactosidase Activity
Assay--
Strains containing the PcooF-lacZ
reporter fusion and plasmid-borne cooA variants were
measured, in the absence or presence of CO, for
-galactosidase
activity as described previously (25).
Purification of WT CooA and CooA Variants--
Purification of
WT CooA and CooA variants (to >95% homogeneity) was performed using
standard procedures as described previously (21). The heme content of
CooA preparations was measured by either using the Soret peak
absorbance from UV-visible absorption spectroscopy (extinction
coefficient of FeIII CooA = 105 mM
1 cm
1 at 423 nm (26)) or the
reduced pyridine hemochromogen method (27).
Fluorescence Polarization Assay for DNA Binding-- In vitro DNA binding of CooA preparations was measured using a fluorescence polarization assay as described (28, 29).
In Vitro Transcription Assays--
The ability of isolated CooA
to activate in vitro transcription under anaerobic
conditions was determined by procedures described previously (13)
except that CooA was bound to DNA for 10 min before the addition of RNA polymerase.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Isolation of Gain-of-function Variants Altered at the Surface of
CooA--
This study began as a screen for mutations in
cooA that would suppress mutations that alter
His77, one of the normal heme ligands in the
FeII (8) and FeII + CO forms (28, 30). The CooA
variants in the starting strains (with either
H77K3 or H77E substitutions)
have a very low level of CO-independent activity and, although they
bind CO with an affinity roughly similar to that of WT
CooA,4 CO binding does not
result in increased activation of transcription (10). We assume that
the forms of WT CooA that are active and inactive for DNA binding exist
in an equilibrium and that CO binding shifts the equilibrium toward the
active form. The replacement of His77 in CooA apparently
shifts that equilibrium slightly toward the active form in the absence
of CO, but CO binding does not further change that equilibrium, so that
the low level of activation in vivo is not increased by the
presence of CO. Using an in vivo
-galactosidase assay
system in E. coli, we screened a pool of cooA-bearing clones in which the region encoding the
effector-binding domain (residues 1-131) of the two His77
variants had been randomly mutagenized. Colonies displaying
significantly higher
-galactosidase activity than did the starting
strains were chosen, and the cooA region was amplified and sequenced.
Because of the nature of the mutagenesis, many of the strains contained
multiple substitutions. Each mutation was recreated by site-directed
mutagenesis in a WT cooA background (i.e. with the WT FeII heme-ligand His77). This allowed us
to identify those mutations that were causative of the increased
-galactosidase activity and to analyze them without the complication
of the mutation affecting the His77 position. From each
original strain with multiple mutations, only one mutation displayed a
clearly mutant phenotype in the WT background, and all subsequent
analyses were limited to these mutations in that background.
Two general classes of suppressor mutations were found: (i) those that render CooA active in the absence of CO and affect residues in its interior (CooA* (10)) and (ii) those that remain CO-dependent for activity and affect surfaces of CooA that might contact RNA polymerase.
The first class of suppressors encoded the following changes in CooA: S78L, F98L, E128K, and D134N. Because of their effector independence, as well as the positions of the affected residues in the CooA structure, they may perturb the pathway by which CO binding to the heme is transmitted to the DNA-binding regions. It appears that a repositioning of the C helices (Fig. 1) with respect to each other plays a role in signal transmission within CooA (8). We assume that these substitutions mimic CO binding by stimulating that repositioning in some fashion.
The second class of suppressors, which is the focus of this paper, consisted of four substitutions: E60G, D94N, E38K, and E41K. The first two affect residues homologous to the AR2 and AR3 regions of CRP (Fig. 1), whereas the latter two fall in an intermediate position. We used the position of these residues as an indicator of the regions of CooA involved in activation and compared these positions to those of residues affecting AR2 and AR3 of CRP and FNR. We verified that the behavior of this second class was not a result of altered protein accumulation or differential heme content, because they all displayed WT levels of heme-containing CooA in extracts (data not shown). It is our working hypothesis that this class was detected in the screen, because they have a significant increase in their ability to interact with E. coli RNAP and that this interaction "traps" the small fraction of these CooA variants that happens to be transiently arranged in the DNA binding conformation.
The AR2 Region of CooA--
In
-galactosidase assays, D94N CooA
showed activity that was greater than that of WT both with and without
CO (Table I). Increases in CO
responsiveness have been reported for a D94A variant of CooA in another
study (31), but no further analysis of the basis of its behavior was
performed. An examination of the local structures of both CooA and CRP
suggested that a gain-of-function substitution in CRP (E96N) maps to
the same surface region and apparently acts by removing an unfavorable
charge·charge interaction between CRP and
-NTD. This residue lies
near the AR2 of CRP, a set of basic residues (His19,
His21, and Lys101) that contact an acidic patch
on
-NTD (15). To further test whether WT CooA actually possesses an
AR2 region, we attempted to construct loss-of-function mutants in this
region on the basis of structural comparisons with CRP. Both T97E and
K26E CooA substitutions were constructed (the former is analogous to
CRP Lys101, and the latter was chosen because of its charge
and position), because we anticipated that they would create
unfavorable charge·charge interactions at the AR2·
-NTD
interface. Both mutants have severely reduced activity in
-galactosidase assays (Table I), consistent with our hypothesis that
this region is important for activation.
|
For a more direct analysis of the basis for the altered behavior of
these CooA variants, T97E and D94N CooA proteins were purified as
described under "Experimental Procedures" and tested for DNA
binding capacity using a fluorescence polarization assay and for
interactions with RNAP using an in vitro transcription assay. Consistent with the suggestion that the alterations affect interactions with RNAP but not with DNA, both variants bound DNA normally in the fluorescence polarization assay with
KD values that were similar to that of WT CooA
(Table I and Fig. 3, A and
B; variants in Figs. 3 and 4
are arranged by functionality). The variants were then tested for their
ability to support CO-dependent transcription in
vitro (13). D94N CooA showed a modest increase in the amount of
transcription product compared with that of WT CooA (Fig. 4,
lower panel), whereas T97E CooA was severely reduced in its
ability to promote transcription from PcooF (Fig. 4,
upper panel).
|
|
It should be noted that the quantitative results of the in vitro and in vivo assays are not directly comparable, both because of inherently different solution conditions and because of the relatively high level of CooA accumulated in vivo. These considerations may be the reason that we detect CO-independent activity in vivo for all of the gain-of-function mutants (Table I) but not in the in vitro assays where CooA is limiting. We assume that the excess of CooA in the in vivo assay allows the detection of the small fraction of protein in the DNA binding configuration when an improved AR region allows the "trapping" of this active fraction.
The identification and characterization of both gain- and
loss-of-function variants of CooA in this region demonstrate that CooA
contains an activating region in the same approximate position as AR2
of CRP and that negatively charged residues on this surface region are
deleterious to its activation function. This is consistent with the
hypothesis that the AR2·
-NTD interaction is electrostatic with a
negatively charged surface on the
-NTD of RNAP interacting with a
positively charged surface of CooA. Because CooA is only the second
member of this large protein superfamily for which the x-ray crystal
structure is known, the similarity in positioning and function of these
regions is striking and suggests that the hypothesis might extend
generally to other divergent members of the CRP family.
The AR3 Region of CooA--
Another CooA variant that increased
-galactosidase activity with and without CO contained an E60G
substitution (Table I), which lies on the exposed
-turn region known
as the 4/5 loop (Fig. 1). Because CooA, unlike CRP and FNR,
lacks a Gly residue in this "turn" region, we wondered if the
phenotype caused by the E60G substitution was due to the loss of the
Glu or the acquisition of the Gly. E60A CooA was constructed and also
exhibited slightly higher than WT activity in vivo (Table
I), suggesting that both the flexibility contributed by the
introduction of the Gly as well as the removal of the Glu side chain
are responsible for the increased activity of E60G CooA.
Although the WT AR3 of CRP is thought to be uninvolved in transcription
activation, the AR3 of FNR has been identified (16) as an important
activation determinant, presumably at the region indicated in Fig. 1
(the structure of FNR has not been solved). Specific acidic residues in
the AR3 of FNR have been hypothesized to contact a basic patch on the
RNAP
70 subunit, which is important for interaction
(16). The structure of the region is also important, because G85A FNR
(Gly85 of FNR is adjacent to the homolog of
Glu60 of CooA) is impaired for AR3 function (18), which is
consistent with the usefulness of Gly at this position for AR3 function
in FNR.
To test the hypothesis that this region is serving as an AR3 in WT
CooA, substitutions in that region were created that should result in a
loss of function by analogy with FNR and CRP. Lys52 is the
residue in CRP that must be removed for its AR3 to function (19), and
the equivalent residues in FNR and CooA are Ile81 and
Val57, respectively. Alanine scanning of the AR3 loop in
FNR has revealed that the I81A substitution reduces in vivo
activity to 30% of WT FNR, suggesting an important role for this
hydrophobic residue.5 We
therefore replaced Val57 of CooA with Lys because the
equivalent residue in CRP is unfavorable for AR3 function. We also
changed residue Glu62, the acidic residue in CooA
homologous to the most important charged residues for AR3 function in
CRP (Glu58 (16)). V57K and E62A CooA both yielded reduced
levels of
-galactosidase activity under all conditions, with V57K
showing almost no activity even under inducing conditions (Table I).
As in the case of the AR2 variants, in vitro analysis was performed with purified proteins. Both isolated E60G and V57K CooA proteins bind DNA with similar affinity as does WT CooA in our in vitro assay (Fig. 3, A and B, and Table I), further suggesting that their differences in vivo are the result of altered interactions with RNAP. Consistent with this hypothesis, V57K CooA was impaired in transcriptional activation in vitro (Fig. 4, upper panel), whereas E60G, the gain-of-function variant found in our initial screen, supported an increase in transcription product (Fig. 4, lower panel).
Although WT CooA does not have a Gly residue in the AR3
-turn, it is
clear from the structure of the effector-free protein, that a turn is
nevertheless made in this region (8). It is our working hypothesis that
the E60G substitution in CooA simply optimizes the region further for
interaction with the sigma subunit of RNAP of E. coli. The
basis for the increased activity apparently caused by the elimination
of the Glu residue (E60A also had modestly higher activity in
vivo) is unclear, but perhaps bulky groups provide some steric
hindrance at this position. The results of these targeted mutations
together with the variant found in our screen suggests that the AR3 of
CooA is functionally similar to those of CRP and FNR, in the sense that
substitutions at apparently similar positions have similar effects in
CooA, CRP, and FNR. The striking effects of substitutions in the
analogous region of CooA strengthen the hypothesis that this region is
of general importance to the CRP superfamily.
AR2 and AR3 Are Not Widely Separated Patches on CooA-- Two of our gain-of-function substitutions found in the initial screen, E38K and E41K, map to a region on the surface of CooA roughly halfway between the putative AR2 and AR3 patches discussed above (Fig. 1). E38A and E41A CooA variants were also constructed and supported activities even higher than those of the original Lys substitutions (Table I), suggesting that it is the removal of the acidic side chains rather than the introduction of the basic side chains that is responsible for the detected activities. Isolated E38A CooA bound target DNA with a similar affinity as did WT CooA in our in vitro assay (Fig. 3B and Table I). Consistent with the notion that these variants are altered in their interaction with RNAP, E38A CooA supported a higher level of transcription product in vitro than did WT CooA (Fig. 4, lower panel).
Because the structure of CooA is rather different from that of CRP in this region, due to the presence of the nearby heme, it is impossible to make a strong case for an analogous region in that protein. Variants that might be similar have been found in FNR, where A61T and F112L were found in a screen for loss-of-function variants (18), and K60R and K60M were found in a screen for suppressors of an AR1 loss-of-function mutation (33). Lys60 of FNR aligns with Glu38 of CooA, and Ala61 and Phe112 of FNR are both spatially adjacent to Lys60 of FNR in a predicted FNR structure based on the structure of CRP and sequence alignment. These residues in FNR have been considered a part of AR3 based on proximity to the 4/5 loop region (18). In any event, the location of Glu38 and Glu41 in effector-free CooA (Fig. 1) strongly suggests that the AR regions on this family of proteins might not be the discrete patches of AR2 and AR3 as shown in the figure but actually reflect a more or less continuous surface of the effector-binding domain capable of interacting with RNAP.
The Putative AR1 Region of CooA--
As outlined in the
introduction, the presence of a functionally important AR1 region in
CooA was suggested by an earlier study that demonstrated the necessity
of RNAP
-CTD for CO- and CooA-induced transcriptional activation
both in vivo and in vitro (13). In CRP, AR1
consists of a set of consecutive amino acids in the DNA-binding domain
(15). None of the gain-of-function variants found in our screen of
randomly mutagenized CooA variants mapped to this region, because we
specifically mutagenized only the effector-binding domain. Although
some residues in the effector-binding domain of FNR appear to be
involved in its AR1 (18, 32), substitutions affecting analogous
residues in CooA were not found due to our limited screen.
Important Implications of These Results-- Irrespective of possible structural similarities of this CooA region with those of CRP and FNR, the position of these CooA variants at Glu38 and Glu41 invites speculation on a possible property of effector binding: repositioning of AR regions for optimal contact with RNAP. Although a comparison of the structure of effector-bound CRP with effector-free CooA shows a significant repositioning of the AR3 region (8) (Fig. 1), this might be the result of new surfaces of the DNA-binding domain being available for interaction with the effector-binding domain after the reorientation caused by effector binding. However, the Glu38-Glu41 region has no obvious connection to the DNA-binding domain but does potentially sense effector binding in the following way: Asn42, adjacent to Glu41, appears to make close contact with His77, the heme ligand that is retained upon CO binding (28, 30). There is strong reason to believe that CO binding perturbs the position of the heme6 and, therefore, His77, Asn42, and Glu41 residues as well. It is therefore possible that CO binding not only triggers a conformational change that supports DNA binding but also directly affects specific residues involved in RNAP interactions. Although the data in this paper do not address this hypothesis, we have found effector-independent CooA variants that display high affinity DNA binding, but not comparably high levels of transcription activation in vivo, suggesting that the causative mutations (typically near the dimer interface) support the conformational changes necessary for DNA binding but not all the changes for optimal interaction with RNAP.6
Another important implication concerns the observations that all three AR regions of CooA appear to be important for function. Until recently, the view was that WT CRP lacks a functional AR3, though one can be revealed by a single substitution, and conversely the AR2 region of FNR is thought not to be important. At least in the case of CRP, more complete mutational analysis has revealed both activating and inhibitory determinants within AR3 (16). Previous results (13), combined with the present study with CooA, are consistent with a view that all members of the family probably have analogues of all three AR regions in close proximity to the appropriate surfaces of RNAP. The functional differences merely reflect the fact that, for a specific activator, some regions make more thermodynamically important contacts than do others, and the important regions have been defined as "functional ARs." In our approach, CooA may be a particularly sensitive test case for these interactions, because we are examining the interactions between R. rubrum CooA and the heterologous RNA polymerase of E. coli, with which CooA has not evolved for optimal interactions.
We should note that the results in this work indicate an importance of the identified residues for proper interaction between CooA and RNA polymerase but do not imply that these residues actually make that contact. A reasonable alternative hypothesis is that some of these residues are important for the proper positioning of nearby residues that actually interact with RNA polymerase.
Conclusions--
The identification of all three AR regions in
CooA, together with the information from its crystal structure, expands
and clarifies the paradigm that has arisen from the analysis of CRP and
FNR. This conservation suggests an early origin for the AR1-, AR2-, and AR3-activating regions in this family of transcriptional activators. The location of "AR-like" regions between AR2 and AR3
suggests that a continuous surface of interaction between the activator
and RNAP is possible. The proximity of this region to the CO-binding
heme is intriguing and suggests a different pathway by which an
effector can lead to the acquisition of transcriptional competence in
this protein family: Effector binding might directly and specifically
modify AR regions, in addition to the alteration in the positioning
of the DNA-binding domains.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Jose Serate for excellent technical assistance; Robert Kerby and Hwan Youn for technical suggestions and critical reading of the manuscript; Richard Gourse, Wilma Ross, Tricia Kiley, and Timothy Donohue for critical suggestions about the work; the Kiley laboratory for technical suggestions; and the Robert Landick laboratory for supplying purified E. coli RNA polymerase.
| |
FOOTNOTES |
|---|
* This work was supported by the College of Agricultural and Life Sciences at the University of Wisconsin-Madison, National Institutes of Health Grant GM53228 (to G. P. R.), Hatch/USDA project 4183 (to R. L. Gourse, for support of T. G.), and a National Research Service Award (to M. V. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Tel.: 608-262-3567;
Fax: 608-262-9865; E-mail: groberts@bact.wisc.edu.
Published, JBC Papers in Press, August 24, 2001, DOI 10.1074/jbc.M105758200
2 R. L. Kerby, unpublished data.
3 Numbering of CRP residues typically starts with the N-terminal Val, whereas numbering of CooA residues begins with the Met1, which is proteolytically removed.
4 M. V. Thorsteinsson, unpublished data.
5 P. J. Kiley, personal communication.
6 H. Youn, unpublished data.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
CRP, E.
coli cAMP receptor protein;
FNR, E. coli fumarate and
nitrate reductase activator protein;
AR1, -2, -3, activating regions
1-3;
PcooF, the promoter of cooF;
PcooM, the promoter of cooM;
RNAP, RNA polymerase;
WT, wild-type;
-CTD, C-terminal domain of the
-subunit of RNA
polymerase;
-NTD, N-terminal domain of the
-subunit of RNA
polymerase;
MOPS, 4- morpholinepropanesulfonic acid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Kerby, R. L.,
Ludden, P. W.,
and Roberts, G. P.
(1995)
J. Bacteriol.
177,
2241-2244 |
| 2. |
He, Y.,
Shelver, D.,
Kerby, R. L.,
and Roberts, G. P.
(1996)
J. Biol. Chem.
271,
120-123 |
| 3. |
Bonam, D.,
and Ludden, P. W.
(1987)
J. Biol. Chem.
262,
2980-2987 |
| 4. |
Bonam, D.,
Lehman, L.,
Roberts, G. P.,
and Ludden, P. W.
(1989)
J. Bacteriol.
171,
3102-3107 |
| 5. |
Ensign, S. A.,
and Ludden, P. W.
(1991)
J. Biol. Chem.
266,
18395-403 |
| 6. |
Shelver, D.,
Kerby, R. L.,
He, Y.,
and Roberts, G. P.
(1995)
J. Bacteriol.
177,
2157-2163 |
| 7. | Spiro, S. (1994) Antonie Leeuwenhoek 66, 23-26[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Lanzilotta, W. N., Schuller, D. J., Thorsteinsson, M. V., Kerby, R. L., Roberts, G. P., and Poulos, T. J. (2000) Nat. Struct. Biol. 7, 876-880[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Passner, J. M., Schultz, S. C., and Steitz, T. A. (2000) J. Mol. Biol. 304, 847-859[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Thorsteinsson, M. V., Kerby, R. L., and Roberts, G. P. (2000) Biochemistry 39, 8284-8290[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Kolb, A., Busby, S., Buc, H., Garges, S., and Adhya, S. (1993) Annu. Rev. Biochem. 62, 749-795[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Lamberg, K. E., and Kiley, P. J. (2000) Mol. Microbiol. 38, 1-12[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
He, Y.,
Gaal, T.,
Karls, R.,
Donohue, T. J.,
Gourse, R. L.,
and Roberts, G. P.
(1999)
J. Biol. Chem.
274,
10840-10845 |
| 14. | Busby, S., and Ebright, R. H. (1999) J. Mol. Biol. 293, 199-213[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Niu, W., Kim, Y., Tau, G., Heyduk, T., and Ebright, R. H. (1996) Cell 87, 1123-1134[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Rhodius, V. A., and Busby, S. (2000) J. Mol. Biol. 299, 295-310[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Lonetto, M. A., Rhodius, V., Lamberg, K., Kiley, P., Busby, S., and Gross, C. (1998) J. Mol. Biol. 284, 1353-1365[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Bell, A., and Busby, S. (1994) Mol. Microbiol. 11, 383-390[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Williams, R.,
Bell, A.,
Sims, G.,
and Busby, S.
(1991)
Nucleic Acids Res.
19,
6705-6712 |
| 20. |
Bell, A.,
Gaston, K.,
Williams, R.,
Chapman, K.,
Kolb, A.,
Buc, H.,
Minchin, S.,
Williams, J.,
and Busby, S.
(1990)
Nucleic Acids Res.
18,
7243-7250 |
| 21. | Shelver, D., Thorsteinsson, M. V., Kerby, R. L., Chung, S. Y., Roberts, G. P., Reynolds, M. F., Parks, R., and Burstyn, J. N. (1999) Biochemistry 38, 2669-2678[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Fox, J. D.,
He, Y.,
Shelver, D.,
Roberts, G. P.,
and Ludden, P. W.
(1996)
J. Bacteriol.
178,
6200-6208 |
| 23. | Vogel, A. M., and Das, A. (1994) Mol. Microbiol. 12, 811-817[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Fromant, M., Blanquet, S., and Plateau, P. (1995) Anal. Biochem. 224, 347-353[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1995) Short Protocols in Molecular Biology , 3rd Ed. , pp. 13-30, John Wiley & Sons, New York |
| 26. |
Shelver, D.,
Kerby, R. L.,
He, Y.,
and Roberts, G. P.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11216-11220 |
| 27. | DeDuve, C. (1948) Acta Chem. Scand. 2, 264-289 |
| 28. |
Thorsteinsson, M. V.,
Kerby, R. L.,
Conrad, M.,
Youn, H.,
Serate, J.,
Staples, C. R.,
Lanzilotta, W. N.,
Poulos, T. J.,
and Roberts, G. P.
(2000)
J. Biol. Chem.
275,
39332-39338 |
| 29. | Lundblad, J. R., Laurance, M., and Goodman, R. H. (1996) Mol. Endocrinol. 10, 607-612[Abstract] |
| 30. | Uchida, T., Ishikawa, H., Ishimori, K., Morishima, I., Nakajima, H., Aono, S., Mizutani, Y., and Kitagawa, T. (2000) Biochemistry 39, 12747-12752[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Aono, S., and Nakajima, H. (1999) Coord. Chem. Rev. 190-192, 267-282[CrossRef] |
| 32. |
Williams, S.,
Savery, N.,
Busby, S.,
and Wing, H.
(1997)
Nucleic Acids Res.
25,
4028-4034 |
| 33. |
Li, B.,
Wing, H.,
Lee, D.,
Wu, H.,
and Busby, S.
(1998)
Nucleic Acids Res.
26,
2075-2081 |
This article has been cited by other articles:
![]() |
S. Mesa, Z. Ucurum, H. Hennecke, and H.-M. Fischer Transcription Activation In Vitro by the Bradyrhizobium japonicum Regulatory Protein FixK2 J. Bacteriol., May 15, 2005; 187(10): 3329 - 3338. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Youn, M. V. Thorsteinsson, M. Conrad, R. L. Kerby, and G. P. Roberts Dual Roles of an E-Helix Residue, Glu167, in the Transcriptional Activator Function of CooA J. Bacteriol., April 15, 2005; 187(8): 2573 - 2581. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Roberts, H. Youn, and R. L. Kerby CO-Sensing Mechanisms Microbiol. Mol. Biol. Rev., September 1, 2004; 68(3): 453 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Youn, R. L. Kerby, M. Conrad, and G. P. Roberts Functionally Critical Elements of CooA-Related CO Sensors J. Bacteriol., March 1, 2004; 186(5): 1320 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Blake, A. Barnard, S. J. W. Busby, and J. Green Transcription Activation by FNR: Evidence for a Functional Activating Region 2 J. Bacteriol., November 1, 2002; 184(21): 5855 - 5861. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Youn, R. L. Kerby, M. V. Thorsteinsson, R. W. Clark, J. N. Burstyn, and G. P. Roberts Analysis of the L116K Variant of CooA, the Heme-containing CO Sensor, Suggests the Presence of an Unusual Heme Ligand Resulting in Novel Activity J. Biol. Chem., September 6, 2002; 277(37): 33616 - 33623. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |